The calcium receptor and calcimimetics

Current Opinion in Nephrology and Hypertension

Volumn 8, Issue 4, 1999, Pages 429-433

  Wada, Michihito ^a   Nagano, Nobuo ^a   Nemeth, Edward F ^b  

^a KIRIN BREWERY CO LTD   (Japan)

^b NPS Pharmaceutical Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; CALCIUM CHANNEL STIMULATING AGENT; CALCIUM ION; CELL SURFACE RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; N [3 (2 CHLOROPHENYL)PROPYL] 1 (3 METHOXYPHENYL)ETHYLAMINE; PARATHYROID HORMONE; PHENYLALKYLAMINE;

ALLOSTERISM; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; HUMAN; NONHUMAN; OSTEITIS FIBROSA; PARATHYROID CELL; PARATHYROID HORMONE RELEASE; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; SIGNAL TRANSDUCTION;

ANILINE COMPOUNDS; ANIMALS; BONE DISEASES; CALCIUM; CALCIUM-BINDING PROTEINS; DRUG DESIGN; HUMANS; HYPERPARATHYROIDISM; KIDNEY FAILURE, CHRONIC;

EID: 0033428419     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199907000-00006     Document Type: Article

References (46)

1. 2+{%N} and other ions as extracellular (first) messengers. Physiol Rev 1991; 71:371-411.
2. 2+{%N}-sensing receptor from bovine parathyroid. Nature 1993; 366:575-580.
3. Brown EM, Pollak M, Hebert SC. The extracellular calcium-sensing receptor: its role in health and disease. Annu Rev Med 1998; 49:15-29.
4. 2+{%N} to function as a versatile extracellular first messenger. Recent Prog Horm Res 1998; 53:257-281.
5. Nemeth EF. Calcium receptors as novel drug targets. In: Principles of bone biology. Bilezikian JP, Raiaz LG, Rodan GA (editors). San Diego: Academic Press; 1996. pp. 1019-1035.
6. Nemeth EF, Steffey ME, Fox J. The parathyroid calcium receptor: a novel therapeutic target for treating hyperparathyroidism. Pediatr Nephrol 1996; 10:275-279.
7. Nemeth EF, Bennett SA. Tricking the parathyroid gland with novel calcimimetic agents. Nephrol Dial Transplant 1998; 13:1923-1925. A concise review highlighting differences between treatment with vitamin D and calcimimetics, which may lead to different effects of these treatments on bone.
8. Nemeth EF, Steffey ME, Hammerland LG, Hung CP, Van Wagenen BC, DelMar EG, et al. Calcimimetice with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 1998; 95:4040-4045. This paper describes for the first time the in-vitro pharmacology of NPS R-467 and NPS R-568, identifying two classes of calcimimetics, type I (classical receptor agonists) and type II (positive allosteric modulators).
9. Hammerland LG, Garrett JE, Hung BCP, Levinthal C, Nemeth EF. Allosteric activation of the Ca{%N}2+{%N} receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568. Mol Pharmacol 1998; 53:1083-1088.
10. Ferry S, Chatel B, Dodd RH, Lair C, Gully D, Maffrand J-P, et al. Effects of divalent cations and a calcimimetic on adrenocorticotropic hormone release in pituitary tumor cells. Biochem Biophys Res Commun 1997; 238:866-873.
11. Mailland M, Waelchli R, Ruat M, Boddeke HGWM, Seuwen K. Stimulation of cell proliferation by calcium and a calcimimetic compound. Endocrinology 1997; 138:3601-3605.
12. Garrett JE, Tamir H, Kifor O, Simin RT, Rogers KV, Mithal A, et al. Calcitonin-secreting cells of the thyroid express an extracellular calcium receptor gene. Endocrinology 1995; 136:5202-5211.
13. Freichel M, Zink-Lorenz A, Holloschi A, Hafner M, Flockerzi V, Raue F. Expression of a calcium-sensing receptor in a human medullary thyroid carcinoma cell line and its contribution to calcitonin secretion. Endocrinology 1996; 137:3642-3848.
14. Ruat M, Snowman AM, Hester LD, Synder SH. Cloned and expressed rat Ca{%N}2+{%N}-sensing receptor; differential cooperative responses to calcium and magnesium. J Biol Chem 1996; 271:5972-5975.
15. Gama L, Breitwiesar GE. A carboxyl-terminal domain controls the cooperativity for extracellular Ca{%N}2+{%N} activation of the human calcium sensing receptor. J Biol Chem 1998; 273:29712-29718.
16. Strader CD, Fong TM, Graziano MP, Tota MR. The family of G-protein-coupled receptors. FASEB J 1995; 9:745-754.
17. Kubo Y, Miyashita T, Murata Y. Structural basis for a Ca{%N}2+{%N}-sensing function of the metabotropic glutamate receptors. Science 1998; 279:1722-1725.
18. Aramori I, Nakanishi S. Signal transduction and pharmacological characteristics of a metabotropic glutamate receptor, mGluR1, in transfected CHO cells. Neuron 1992; 8:757-765.
19. Thomsen C, Mulvihill ER, Haldeman B, Pickering DS, Hampson DR, Suzdak PD. A pharmacological characterization of the mGluR1 alpha subtype of the metabotropic glutamate receptor expressed in a cloned baby hamster kidney cell line. Brain Res 1993; 619:22-28.
20. Ward DT, Brown EM, Harris HW. Disulfide bonds in the extracellular calcium-polyvalent cation-sensing receptor correlate with dimer formation and its response to divalent cations in vitro. J Biol Chem 1998; 273:14476-14483.
21. Bai M, Trivedi S, Brown EM. Dimerization of the extracellular calcium-sensing receptor (CaR) on the cell surface of CaR-transfected HEK293 cells. J Biol Chem 1998; 273:23605-23610.
22. Torres A, Rodriguez M, Felsenfeld A, Martin-Malo A, Llach F. Sigmoidal relationship between calcitonin and calcium: studies in normal, parathyroidectomized, and azotemic rats. Kidney Int 1991; 40:700-704.
23. McGehee DS, Aldersberg M, Liu K-P, Hsuing S-C, Heath MJS, Tamir H. Mechanism of extracellular Ca{%N}2+{%N} receptor-stimulated hormone release from sheep thyroid parafollicular cells. J Physiol 1997; 502:31-44.
24. Heath H III, Sanguinetti EL, Oglesby S, Marriott TB. Inhibition of human parathyroid hormone secretion in vivo by NPS R-568, a calcimimetic drug that targets the parathyroid cell-surface calcium receptor. Bone 1995; 16 (Suppl. 1):85S.
25. Silverberg SJ, Bone HG III, Marriott TB, Locker FG, Thys-Jacobs S, Dziem G et al. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N Engl J Mod 1997; 337:1506-1510.
26. Collins MT, Skarulis MC, Bilezikian JP, Silverberg SJ, Spiegel AM, Marx SJ. Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 1998; 83:1083-1088. This paper describes the first therapeutic use of the calcimimetic NPS R-568 in a patient with parathyroid carcinoma that could not be treated with any conventional therapies. The results observed with the patient are encouraging, despite the limitations of drawing a conclusion on a single patient. Also see editorial by Off [27].
27. Off SM. Calcimimetics - New drugs with the potential to control hyperparathyroidism [Editorial]. J Clin Endocrinol Metab 1998; 83:1080-1082.
28. Antonsen JE, Sherrard DJ, Andress D. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Kidney Int 1998; 53:223-227. This paper describes the short-term effect of NPS R-568 on plasma PTH levels in hemodialysis patients with mild hyperparathyroidism. The authors observed not only the decrease in plasma levels of PTH, but also the increase in those of calcitonin, both of which may contribute to the reduction in bone turnover in osteitis fibrosa.
29. Akizawa T, Suzuki M, Tominaga Y, Saito A, Uchida E, Kawaguchi Y, et al. Acute effect of calcimimetic agent (CA) on hemodialysis (HD) patients with secondary hyperparathyroidism [2HPT). J Am Soc Nephrol 1995; 9:561A. The authors report the short-term effect of NPS R-568 on plasma PTH levels in hemodialysis patients, some of whom suffered from severe hyperparathyroidism (average immunoreactive PTH levels > 1000 pg/ml).
30. Wada M, Furuya Y, Sakiyama J-I, Kobayashi N, Miyata S, Ishii H, et al. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency: control of parathyroid call growth via a calcium receptor. J Clin Invest 1997; 100:2977-2983.
31. Wada M, Ishii H, Furuya Y, Fox J, Nemeth EF, Nagano N. NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 1998; 53:448-453. The authors explored the effects of the calcimimetic NPS R-568 on bone structure and strength in rats with secondary hyperparathyroidism. Also see editorial by Sherrard [32].
32. Sherrard DJ. Calcimimetics in action [Editorial]. Kidney Int 1998; 53:510-511.
33. Heath H III. Primary hyperparathyroidism: recent advances in pathogenesis, diagnosis, and management. Adv Intern Med 1992; 37:275-293.
34. Antonsen JE, Sherrard DJ. Renal osteodystrophy: past and present. Semin Dial 1996; 9:296-302.
35. DrŸeke TB. The pathogenesis of parathyroid gland hyperplasia in chronic renal failure. Kidney Int 1995; 48:259-272.
36. Parfitt AM. The hyperparathyroidism of chronic renal failure: a disorder of growth. Kidney Int 1997; 52:3-9.
37. Navoh-Many T, Rahamimov R, Livni N, Silver J. Parathyroid cell proliferation in normal and chronic renal failure rats: the effects of calcium, phosphate, and vitamin D. J Clin Invest 1995; 96:1786-1793.
38. Slatopolsky E, Finch J, Denda M, Ritter C, Zhong M, Dusso A, et al. Phosphorus restriction prevents parathyroid gland growth: high phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 1996; 97:2534-2540.
39. Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993; 92:1436-1443.
40. Kifor O, Moore J, Wang P, Goldstein M, Vassilev P, Kifor I, et al. Reduced immunostaining for the extracellular Ca{%N}2+{%N}-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 1996; 81:1598-1606.
41. Gogusev J, Duchambon P, Hory B, Giovannini M, Goureau Y, Sarfati E, et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997; 51:328-336.
42. Koiwa F, Ogata H, Kinugasa E, Akizawa T, Ideura T. Correlation of calcium receptor (CaR), vitamin D receptor (VDR) and cell proliferation in parathyroid glands (PTG) with secondary hyperparathyroidism (2HPT). J Am Soc Nephrol 1998; 9:667A.
43. Fox J, Chin J, Nemeth EF, Furuya Y, Ishii H, Wada M, et al. Effects of a calcimimetic on the parathyroid glands of rats with chronic renal insufficiency and severe secondary hyperparathyroidism. J Am Soc Nephrol 1997; 8:573A.
44. Parisian M, Dempster DW, Shane E, Bilezikian JP. Histomorphometric analysis of bone in primary hyperparathyroidism. In: The parathyroids. Bilezikian JP, Levine MA, Marcus R (editors). New York: Raven Press; 1994. pp. 493-503.
45. Hebert SC. Extracellular calcium-sensing receptor: implications for calcium and magnesium handling in the kidney. Kidney Int 1996; 50:2129-2139.
46. Hebert SC. The calcium-ion-sensing receptor. Clin Exp Nephrol 1998; 2:204-210.